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Summary A bispecific mouse monoclonal antibody (mAb) that recognises carcinoembryonic antigen (CEA) with one binding site and vinblastine (VLB) with the other was used, and its in vivo immunosuppressive effect
specific for anti-mouse immunoglobulin (Ig) was studied. The antibody was incubated with VLB at a molar ratio (MR) of 1:1, and administered i.v. to rabbits. Control animals received either the MAb alone, or the MAb with VLB covalently linked (MR 1:1), or the parental anti-CEA with equimolar amount of VLB. Seven days later, the rabbit anti-mouse Ig primary response was measured, and found to be almost 55% reduced in the animals that received the VLB 'loaded' MAb. In vivo kinetics and stability experiments revealed that the T1 of the MAb was 68 ±5 h, whereas free VLB disappeared within minutes. It was concluded that as soon as the drug dissociates from the antibody's binding site, it is rapidly removed. This problem was overcome by subcutaneously implanting osmotic mini-pumps containing VLB. The pumps released the drug at a constant
rate for a period > 1 week, saturating the antibody's binding site. Under these conditions rabbits developed 80% less anti-mouse Ig antibodies when the bispecific antibody was administered (compared with the parental anti-CEA). The immunosuppression observed was specific for the mouse Ig, under conditions compatible with the full clinical therapeutic potential of the MAb. In conclusion, these experiments show, that it is possible to develop hybrid antibodies that can act as a 'lethal bait' to any specific lymphocyte in vivo, thus preventing undesirable responses against the xenogeneic MAb.
Antibodies have been used in patients with cancer for in vivo
tumour localisation and treatment, and encouraging results
have been shown occasionally on early tumour detection
(Mach et al., 1981; Epenetos et al., 1986; Kalofonos et al.,
1989) or effective cancer treatment (McCardle et al., 1966;
Miller et al., 1982; Spittler et al., 1987; Epenetos et al., 1987;
Byers & Baldwin, 1988). The introduction of the monoclonal
antibody technique has played an important role in recent
developments, since it enabled the production of a wide
variety of monospecific antibodies in large quantities. Thus
today, antibodies can be produced in vitro, and selected for
properties that suit individual needs, such as affinity and
isotype. In addition, progress in chemical modifications has
enabled the production of novel immunoconjugates. Mono-
clonal antibodies (MAbs) can be conjugated to suitable
radionuclide, enzymes, toxins (of plant or bacterial origin)
and drugs, in order to increase their potency.
However, a major limitation to the successful in vivo
clinical application of MAbs is that the majority of diagnos-
tic and therapeutic antibodies are of rodent origin, and hence
are recognised by the host as foreign. Patients can mount an
immune response against the xenogeneic antibody (Schroff et
al., 1985; Goldman-Leikin et al., 1988), which is dose depen-
dent (Sears et al., 1987), initially directed against the constant
region (Courtenay-Luck et al., 1986), but later extended
against the whole molecule including the idiotope (Herlyn et
al., 1986; Courtenay-Luck et al., 1988). Even if a successful
treatment protocol is devised, the production of human anti-
mouse immunoglobulin (Ig) antibodies can limit the efficiency
of the administered therapeutic antibody by removing it from
circulation (Zimmer et al., 1988). As a consequence, the
amount of the therapeutic antibody that could reach the
tumour is very low, and continuously decreases upon further
injections, as the anti-mouse Ig response rises. Furthermore,
the in vivo antibody/antibody immune complexes may also
lead to type III hypersensitivity (serum sickness), that can
cause an inflammatory response with severe tissue damaging
consequences.
The development of human anti-tumour antibodies, when
readily available, may solve this problem, even though anti-
idiotypic antibodies can be a source of difficulties. Thus,
xenogeneic antibodies will continue to be in extensive use in
a variety of clinical studies. It is therefore of paramount importance to reduce or abolish the patients' response against these rodent antibodies if we wish antibody-mediated
manipulation of cancer to be successful.
The overall aim of this study was to identify ways by which the host's immune response to xenogeneic Ig, admini-
stered for therapeutic purposes, could be reduced or elimin-
ated. We describe an approach towards the construction of
Igs potentially 'lethal' to lymphocytes in vivo. Theoretically, if
an antigen (the monoclonal antibody in this case) is con-
jugated to a toxic compound, it should kill rather than drive
the patient's B-cells to differentiation and antibody secretion, in agreement with the concept of antigen 'suicide' first de-
scribed by Humphrey & Keller, 1969. Thus, only the B-cell
population that bears Ig receptors specific for the 'lethal'
antigen will be deleted. Specific immunosuppression, and per- haps even tolerance, may be achieved under conditions where
the rest of the immune system remains intact and fully potent
to react against potential pathogens.
The bispecific antibody 28.19.8 recognises a tumour asso-
ciated antigen (carcinoembrionic antigen, CEA) with one
binding site and the Vinca alkaloids with the other (Corvalan & Smith, 1987). This antibody has been used successfully to
target free, unmodified Vinca alkaloids to tumours expressing CEA, with significant suppression of tumour growth (Cor- valan et al., 1987a,b; Corvalan et al., 1988; Smith et al., 1990). In this study we have examined whether 28.19.8 (from here onwards called HH antibody) when 'loaded' with the
cytostatic drug vinblastine (VLB) and administered to
rabbits, could play the role of 'lethal' antigen, eliminate
immunocompetent cells in vivo, and thus specifically suppress the anti-mouse Ig response. The results, if successful, could
be of importance not only to immunotherapy, but also to
other clinical situations such as autoimmunity, allergy or
transplantation.
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Materials and methods
Animals
Male 1/2 'lop' rabbits (Froxfield Farm, UK), 3-4 kg, were
used throughout this study.
Antigen
The bispecific mouse monoclonal antibody 28.19.8. was used
as immunogen for rabbits. This antibody was produced at
the Lilly Research Centre, Eli Lilly and Co., Surrey, UK. It
is a mouse LgGl-IgG2a hybrid, derived from the fusion of a
hybridoma cell line producing anti-CEA monoclonal anti-
bodies (designated as 11.285.14), and spleen cells from a
mouse previously immunised with vindesine-bovine serum
albumin (VDS-BSA). This hybrid-hybrid (HH) antibody
designated as 28.19.8) has the capacity of binding CEA with
one binding site and Vinca alkaloids with the other, the latter
with an affinity constant of -5 x 108 M-1 (unpublished data)
as determined by equilibrium dialysis. It has been shown,
that when 'loaded' with vindesine (Corvalan et al., 1987a) or
vinblastine (Corvalan et al., 1987b), it is toxic to CEA exp-
ressing cells, not only in vitro but also in vivo against human
tumour xenografts in nude mice (Corvalan et al., 1988; Smith
et al., 1990).
Prior to each administration, the ability of the bispecific
antibody to bind VLB was checked. This was done by either
ELISA or gel filtration. For the ELISA, 96-well plates (Steri-
lin, UK) were coated with 200 ng well VLB-BSA; the test
antibody was applied, followed by an anti-mouse Ig-horse-
radish peroxidate (HRP, Amersham, UK) at 1:500 dilution.
The substrate ABTS was applied, and the absorbance was
measured at 405 nm (Titertek, Flow Laboratories, UK). For
the gel filtration, the test antibody was incubated with 3H-
labelled VLB (3H-VLB, Amersham), and passed through
Sephadex G-25 or G-50 columns (Pharmacia, Sweden). Frac-
tions were collected, and the radioactivity was measured in a
P-counter (LKB-Wallac, Sweden). Internal controls for
quenching were introduced in each sample and the original
counts corrected accordingly.
The immunoreactivity of the parental anti-CEA antibody
was also tested by ELISA: Nunc (UK) 96-well plates were
coated with 1 jig well purified CEA at room temperature
(RT), overnight. The test antibody was added, followed by a
rabbit anti-mouse Ig-alkaline phosphatase (prepared by Lilly
Research Centre, Eli Lilly and Co., UK). The substrate was
was p-nitro phenol phosphate (p-NPP, Sigma, UK), and the
absorbance was measured at 410 nm, using a Titertek
spectrophotometer.
Vinblastine-conjugates
The hybrid-hybrid/VLB mixture was prepared by mixing the
antibody with VLB sulphate (Eli Lilly, USA) for 15min at
RT. Prior to each administration all antibody and antibody-
VLB mixtures were tested and found to be free of aggregates.
This was done by size exclusion chromatography using a
Superose 6 column connected to an FPLC system (Phar-
macia).
Vinblastine was covalently linked to a bispecific antibody
as follows:-N-hydroxy succinimide ester of 4-succinoyl des-
acetyl vinblastine (Eli Lilly, USA) was allowed to bind to the
bispecific antibody as antigen, whilst stirred for 1 min in
phosphate buffered saline (PBS), pH 6.2, at 4°C. The starting
MR was five vinblastine esters per antibody molecule. The
antibody/vinblastine ester complex was immediately separ-
ated from free ester by size exclusion chromatography (P-6
column, Biorad, UK) in borate buffer, pH 8.6, at 4°C. The
complex was warmed to RT, and stirred for 1 h. After over-
night dialysis in PBS, pH 7.4, the conjugation ratio was
estimated by dual wavelength spectroscopy at 270 and
280 nm, and found to be 1.03 VLB/antibody. As tested by
ELISA, the immunoreactivity of the conjugate for CEA
remained intact, whereas it was reduced to 2.7% for VLB,
when compared with the unconjugated antibody.
Similarly, VLB was conjugated to BSA using the same
succinamide ester as above. The mixture was incubated in
borate buffer, pH 8.6, for 4 h at RT, and BSA-VLB was
purified from unbound VLB ester by gel filtration (P-6
column, Biorad) in PBS, pH 7.4. The MR was found to be
3.75:1 (starting MR 15:1).
Kinetics
The presence of vinblastine was measured in rabbits when
administered i.v., when constantly infused using a mini
osmotic pump designed to deliver 10 ,ul h-' for a week (Alzet
Co., Palo Alto, USA) implanted subcutaneously, and when
co-injected i.v. with the bispecific antibody. Prior to adminis-
tration the drug was mixed with a trace amount of 3H-VLB
(Amersham), blood samples were taken at regular time
points, and the radioactivity in the serum was measured
using a P-counter.
The kinetics of the bispecific monoclonal antibody, when
administered i.v. to rabbits, were measured as follows: the
antibody was injected, and blood samples were taken at
various intervals for 5 days. The blood was left to clot, the
serum was then removed and incubated in 96-well plates
(Sterilin) coated with 200 ngwell VLB-BSA. After 2 h the
plate was washed with PBS/0.05% tween 20, pH 7.4, and
incubated with an anti-mouse Ig-HRP (Amersham) at 1:500
dilution, for 1 h. The plate was washed, and the absorbance
was measured at 405 nm using azino-di-[3-ethylbenzothiazo-
linesulphonate] (ABTS) substrate. The results were given as
areas under the sigmoidal curve, obtained from the serial
dilutions (1:10) of the test sera. The value obtained from the
serum sample taken immediately after administration was
regarded as the injected dose (100%).
Immunisation protocols
The immunisation schedule of the first experiment was as
follows: four groups of three rabbits each were injected i.v.
(ear vein) with 1 mg of the following antigens: (a) the
bispecific, hybrid-hybrid, mouse monoclonal antibody 28.19.8
mixed with VLB (as VLB sulphate, Eli Lilly, USA) (HH/
VLB) at a molar ratio (MR) of 1:1 (equivalent to 5.45 g
VLB/rabbit), (b) the parental anti-CEA antibody 11.285.14
mixed with 5.45jg VLB (anti-CEA/VLB), (c) the bispecific
monoclonal antibody 28.19.8 alone (HH) and lastly (d) the
bispecific monoclonal antibody 28.19.8 covalently linked to
VLB (HH-c-VLB), on the Vinca binding site, at MR of 1:1.
All rabbits were bled on day 6, and boosted i.p. with 1 mg of
the parental anti-CEA antibody on day 7. They were bled
again on days 10, 14, 21 and 28. On day 29 the four groups
received i.v. 1 mg of the initial immunogen as on day 0. A
blood sample was taken 7 days later (day 35), and on day 36,
all rabbits were boosted again i.p. with 1 mg of the anti-CEA
(as on day 7). They were bled on days 39, 43 and from then
on, once weekly for a period of 3 weeks (up to day 64). In
addition, 4 mg of ovalbumin (OVA) (Sigma, UK) was simul-
taneously administered with each injection of the antigen.
The second experiment consisted of two groups of six
rabbits each. In all animals, an osmotic mini-pump of the
same characteristics as described above and filled with 1 mg
of VLB in distilled water was implanted subcutaneously in
the dorsal region between the scapulae. Five days after
implantation, the two groups received i.v. 1 mg of either the
bispecific antibody (HH) or the parental anti-CEA. The
animals were bled, and the primary anti-mouse Ig response
assessed on days 7, 12 and 60 after administration of the
immunogen.
Measurement ofcirculating immunoglobin and vinblastine
The concentration of the mouse antibodies (used as immuno-
gens i.e. HH or anti-CEA) in the circulation was measured
by ELISA. Ninety-six well microtitre plates (Nunc) were
coated with 1 gig well purified CEA. Test serum was added,
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mouse Ig-alkaline phosphatase conjugate and p-NPP substrate.
The absorbance was measured at 410 nm, by a multiscan
spectrophotometer, a standard curve plotted, using known
concentrations of the corresponding antibody (mixed with
rabbit serum), and the circulating immunogen quantitated.
Similarly the concentration of circulating VLB was esti-
mated as previously described (Corvalan & Smith, 1987):
ELISA plates were coated with CEA (as above), and a
saturating amount of the bispecific antibody was incubated
for 1 h at RT. The plates were washed with PBS/0.05%
Tween 20, pH 7.4, and the test serum was added. Circulating
VLB was detected, by direct competition with VLB-alkaline
phosphatase. The substrate used was p-NPP, and the absor-
bance was measured at 410 nm as above. This was performed
after it was established that there was no HH antibody in
circulation to interfer with our assay. The assay is sensitive to
less than 1 ng VLB ml-'.
Measurement ofthe anti-immunoglobulin response
The rabbits' responses against the mouse monoclonal anti-
bodies administered were measured by ELISA. Ninety-six
well plates were coated with the antibody used as antigen,
and the corresponding test sera were added at 10-fold dilu-
tions and tested in duplicates. Rabbit anti-mouse Ig anti-
bodies were detected by a species-specific anti-mouse Ig-HRP
second layer and ABTS substrate. After plotting the optical
densities vs the serum dilutions, the results were analysed by
a weighted non linear least squares of 4 parameters logit (De
Savigny & Voller, 1980; Karpinski et al., 1987). The results
were expressed as areas under the serum titration sigmoidal
curve as this method has been duly validated before (Sedg-
wick et al., 1983; Crichton et al., 1990). Before any experi-
ment, it was ensured that none of the rabbits used had any
pre-existing anti-mouse Ig antibodies. Statistical analysis of
the data was performed using the Student's t-test on the logs
of the areas under the titration curves.
Measurement ofthe anti-ovalbumin andanti-vinblastine
response
The rabbits' response to the administered VLB or OVA was
measured with an ELISA similar to the above. The only
difference was that the plates were coated with either 200 ng
well VLB-BSA or 500 ng well OVA. In the case of anti-VLB
response, all positive sera were also tested against BSA alone,
in order to prove the presence of true anti-VLB antibodies.
Before each experiment, rabbits were chosen that did not
have any pre-existing anti-VLB or anti-OVA antibodies.
Statistical analysis of the data was also performed using the
Student's t-test on the logs of the area.
Results
Kinetics ofvinblastine
The kinetics of free VLB in rabbits were measured after i.v.
administration. Serum samples were taken at various time
points up to 15 min. The drug was rapidly removed from the
circulation; 10 min after administration approximately 1% of
the injected dose remained in the blood (Figure 1). The
clearance of VLB when simultaneously administered with the
hybrid-hybrid antibody was also measured over a period of
5 h. When VLB was injected i.v. into a rabbit in the presence
of HH at a Mr of 1:1, the drug was rapidly removed from
the circulation, though not as rapidly as free VLB. As shown
in Figure 1, at 10 min after administration approximately
15% of the injected amount of VLB was in circulation
associated with the HH antibody.
In addition, the kinetics of free VLB were studied after
infusion from a subcutaneously implanted osmotic mini-
pump. The pump was filled with VLB and the animal was
bled daily for up to 20 days. It was found that the drug was
released slowly into the circulation, and as shown in Figure
2, its concentration increased with time. The amount of VLB
reached a peak 7-9 days after implantation, after which it
slowly dropped back to zero (Figure 2). It was estimated that
from day 5 to day 12 there was a 'window', where the total
amount of VLB in the blood was over 5fg, i.e. a MR of
approximately 1:1 when 1 mg of HH is injected; amount
sufficient to saturate the MAb.
Kinetics ofthe monoclonal antibody
The hybrid-hybrid antibody was injected i.v. into a rabbit,
and serum samples were collected at various time points for 5
days. The amount of antibody present in circulation at each
time point was determined by its ability to bind VLB immu-
nobilised onto an ELISA plate. The amount of HH present
in the blood - and also capable of binding to its antigen -
remained unchanged (100% of the injected dose) for up to
6 h after administration. From that point on, it diminished
with a T1 of 68 ± 5 h (Figure 3).
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Figure 1 Clearance of vinblastine in rabbits, after i.v. adminis-
tration. 0, free vinblastine; *, vinblastine in the presence of the
hybrid-hybrid antibody.
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Figure 2 Total concentration of vinblastine in the serum of
rabbits when the drug is constantly infused by a subcutaneously
implanted osmotic mini-pump.
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Figure 3 Clearance of the bispecific antibody in rabbits after i.v.
administration.--~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
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Anti-mouse immunoglobulin response
In the first experiment, three rabbits/group were primed i.v.
with the HH, HH covalently conjugated with VLB, HH
mixed with VLB and anti-CEA mixed with VLB (the last
three preparations were used at a MR of 1:1). When the
primary anti-mouse Ig response was measured 7 days later,
we found that rabbits receiving the HH/VLB mixture res-
ponded significantly less to the mouse Ig. As shown in Figure
4, rabbits primed with the VLB- 'loaded' HH, developed
53.4% less anti-mouse Ig antibodies, than those that received
HH alone (MeanHH/VLB = 1.368 ± 0.370, MeanHH = 2.932 ±
0.304, P = 0.004), 52.4% less than those receiving the HH
antibody covalently linked to VLB (Mean = HH-c-VLB =
2.875 ± 0.407, P = 0.006) and 59.8% less than those receiving
the parental anti-CEA antibody mixed with VLB (MeanacEA/
VLB= 3.401 ± 0.018). Only two animals were available for
comparison in this last control group. The titres of these two
animals were very similar to those in the other control
groups injected with HH alone and HH covalently coupled
to VLB, respectively.
On day 7, all groups were boosted i.p. with the anti-CEA
antibody. As shown in Figure 5, the anti-mouse Ig secondary
response was measured over a period of 3 weeks. We found
that initially there was no difference in the response among
the four groups. Nevertheless, the anti-mouse Ig titres started
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Figure 4 Rabbit anti-mouse Ig primary response, when the fol-
lowing immunogens were administered i.v. in groups of three
rabbits: the hybrid-hybrid antibody (HH), the hybrid-hybrid anti-
body covalently linked to vinblastine (HH-c-VLB), the anti-CEA
antibody mixed with vinblastine (a-CEA/VLB) and the hybrid-
hybrid antibody mixed with vinblastine (HH/VLB). The a-CEA/
VLB group consisted of only two rabbits.
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Figure 5 Rabbit anti-mouse Ig secondary response, measured
over a period of 4 weeks, when four groups of rabbits were
primed i.v. (day 0) with: 0, the hybrid-hybrid antibody (HH),
*, the hybrid-hybrid antibody covalently linked to vinblastine
(HH-c-VLB), *, the anti-CEA antibody mixed with vinblastine
(a-CEA/ VLB) and O, the hybrid-hybrid antibody mixed with
vinblastine, and subsequently boosted i.p. (day 7) with the a-CEA
antibody.
to drop more rapidly (on day 21) in the group of rabbits that
were primed with the HH/VLB mixture. By day 28, the
anti-mouse Ig response for this group (mean 2.010±0.114)
was 32% less (P = 0.021) than those receiving the HH anti-
body alone (mean 2.950 ± 0.180), 23% less (P = 0.035) than
those receiving HH antibody covalently linked to VLB (mean
2.609 ± 0.088) and 28% less (P = 0.004) than those receiving
the parental anti-CEA antibody mixed with VLB (mean
2.780 ± 0.056). The complete results are presented in Figure 5.
On day 29, the four groups received an i.v. injection of
their corresponding antigens (Igs) (as on day 0), and 7 days
later they were boosted with an i.p. injection ofthe anti-CEA
antibody alone (as on day 7). The humoral response was
followed up to day 64; we observed no difference in the
rabbits' anti-mouse Ig responses among all groups, irrespec-
tive of the preparations with which they had been primed
and boosted.
In the second experiment, 12 rabbits were implanted with
osmotic mini-pumps, releasing VLB into the circulation at a
constant flow rate. Five days after implantation, six rabbits
received the HH antibody and the other six the parental
anti-CEA. The rabbits' primary reponse was measured on
days 7, 12 and 60 post antibody administration. As shown
in Figure 6a, the response of rabbits injected with the HH
had a 78% lower response than in the group receiving the
control antibody (MeanHH = 0.480 ± 0.237, Meana-cEA =
2.177 ± 0.802, P<0.001). On days 12 and 60, the reduction
in the anti-mouse Ig response was found to be 55%
(MeanHH = 1.799 ± 0.614, MeanacEA = 3.587 ± 0.463, P=
0.001) and 63% (MeanHH = 1.128 ± 0.345, Meana<EA = 3.007+
0.941, P<0.001) respectively (Figure 6b and c). The overall
anti-mouse Ig response, over the period of 60 days, is shown
in Figure 7. The mean reduction in the anti-mouse Ig res-
ponse for the rabbits that received the bispecific antibody,
was 60%, as calculated by the area under the curve.
For this experiment, where the drug was delivered by an
osmotic mini-pump, we measured the levels of HH and
anti-CEA still in circulation, on day 7 and 12 after admini-
stration. As shown in Table I, five our of the six rabbits that
received the HH antibody (and responded significantly less to
it), still had detectable levels of the MAb in circulation. The
6th rabbit was the one that developed the highest anti-mouse
Ig response of this group (Figure 6a). In addition, the five
out of six rabbits that were injected with the anti-CEA
antibody (and responded very well to it), we did not detect
any anti-CEA in the circulation. In only one rabbit (number
7) could we detect circulating mouse Ig, and that was the one
that developed the lowest anti-mouse Ig response of this
group (Figure 6a). By day 12 there was no mouse immuno-
globutin in circulation. The VLB levels in the blood were
also measured on day 12. As shown in Table I, there was still
VLB in circulation. There appeared to be no relationship
between the kind of immunogen administered and the
amount of circulating VLB.
Anti-ovalbumin andanti-vinblastine response
Rabbits were also immunised with OVA as an irrelevant
antibody. The anti-OVA response was followed throughout
the experiments indicating that, despite variability, there was
no significant difference in the animals' ability to make anti-
bodies against OVA, irrespective of the immunoglobulin pre-
paration that they had simultaneously received (Table II). All
animals were also tested for an anti-VLB response. No anti-
VLB antibodies were observed under the immunisation con-
ditions used.
Toxicity
All animals remained alive and well throughout and long
after the experiments. No side effects were observed at the
doses of vinblastine and mouse antibodies that were admin-
istered, and no adverse reactions were seen due to the
implantation of the mini-pump, apart from a transient and
self-limiting erythema.XENOGENEIC MONOCLONAL ANTIBODIES IN CANCER MANAGEMENT 285
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Figure 6 Primary anti-mouse Ig response, when the hybrid-
hybrid and the a-CEA antibodies were administered iv. to two
groups of six rabbits, under constant infusion of vinblastine. The
response was measured on days 7 a, 12 b and 60 c post adminis-
tration of the antibodies.
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Figure 7 Mean overall primary anti-mouse Ig response, when
the hybrid-hybrid (HH) and the a-CEA antibodies were admini-
stered i.v. to two groups of six rabbits, under constant infusion of
vinblastine.
Table I Concentration of the hybrid-hybrid (HH) and the anti-CEA
(a-CEA) antibodies in rabbits' sera, 7 and 12 days after i.v. administra-
tion
Antibody Vinblastine
Day 7 Day 12 Day 7 Day 12
Rabbit Immunogen (ngml') (ngml-') (ngml-') (ngml-')
1 108 - N.T. 4.5
2 237 - N.T. <0.4
3 83 - N.T. 4.3
4 HH 26 - N.T. N.T.
5 77 - N.T. <0.4
6 - - N.T. 7.8
7 124 - N.T. <0.2
8 - - N.T. N.T.
10 a-CEA - _ N.T. 1.3 1 0 ~~- N.T. <0.13 11 - - N.T. 27
12 N.T. N.T. N.T. 1.3
Concentration of vinblastine in rabbit's sera at the same time as
above. The drug was constantly infused into the rabbits by an osmotic
mini-pump, subcutaneously implanted 5 days before administration of
the antibodies.
Table II Anti-ovalbumin (OVA) response for four groups of rabbits
primed with OVA on day 0 in combination with either HH antibody,
HH-c-VLB, a-CEA/VLB, or HH/VLB, respectively
Day HH HH-c-VLB a-CEA/VLB HH/VLB
6 0.265±0.063 0.149±0.016 0.183 0.265±0.060
10 1.169±0.494 0.555±0.331 0.640 1.195±0.401
14 1.992±0.742 1.672±0.349 1.453 1.590±0.421
21 1.602±0.531 1.395±0.392 1.285 1.412±0.421
28 1.313±0.339 1.220±0.350 1.127 1.051 ±0.292
Allrabbits wererechallenged withthe sameimmunogensafter7days. *Only twoanimals in this group. Pvalues were >0.1 fordays 6 and 10
and >0.5 for all the rest.
Discussion
It has previously been shown by many investigators that
when an antigen is covalently linked to plant toxins or drugs,
it can specifically inactivate lymphocytes that bind to it in
vitro (Vitetta et al., 1983; Shelton et al., 1988). Moreover, in
certain cases antigen-toxin/drug conjugates were found to
abrogate specifically the response of animals against the
administered antigen (Shelton et al., 1988; Brust et al., 1987;
Diener et al., 1986; Durrant et al., 1989). We have used a
novel drug-conjugate consisting of a bispecific mouse mono-
clonal antibody, that recognises Vinca alkaloids with one
binding site and CEA with the other. This hybrid-hybrid
antibody when mixed with vinblastine, forms a complex that
is stable in vitro, as it was estimated by gel filtration (see
Methods), even in the presence of serum. We investigated the
possible in vivo immunosuppressive effects of this monoclonal
antibody/VLB complex, when it was administered 'loaded'
with vinblastine to rabbits.
We found that when this bispecific monoclonal antibody
was administered i.v. to rabbits simultaneously with VLB, at
a MR of 1:1, the primary anti-mouse Ig response was
reduced by approximately 55% (Figure 4). The immunosup-
pression observed was specific for the mouse Ig, since the
response against an irrelevant antigen (OVA) was normal
(Table II). Further proof that the amount of VLB injected
was not responsible for a general, non specific immunosup-
pression, was that when the drug was co-injected with the
control anti-CEA antibody, the anti-mouse Ig response was
not reduced (Figure 4). Interestingly, when the hybrid-hybrid
antibody was covalently linked to VLB, it did not show any
immunosuppressive effect (Figure 4). It would therefore
appear, that the hybrid-hybrid/VLB complex is captured by
B-cells that have receptors specific for the mouse Ig admin-
istered. The VLB subsequently dissociates and inactivates the
mouse Ig-specific B-cells, which eventually die before they
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can proliferate, mature and secrete immunoglobulin. Dissoc-
iation of the drug from the MAb appears to be necessary for
this action, since the covalently linked antibody-VLB com-
plex is inactive (Figure 4).
Even though B-cell tolerance has been classically described
as short lived (Chiller & Weigle, 1973; see Moreno, 1982 for
a review), the specific suppression induced by HH complexed
with VLB does not appear to be tolerance. The suppressed
animals responded equally well to a subsequent challenge
with anti-CEA antibody, although their anti-mouse Ig anti-
body levels fell earlier than those in the control groups
(Figure 5). Moreover, a further challenge with the immuno-
suppressive HH/VLB mixture (MR 1:1), did not seem to
affect the immune response of animals previously primed
with mouse Ig. For over 2 months, the levels of anti-mouse
Ig antibodies were the same in the animals that received the
HH/VLB complex (1st and 3rd immunisation, anti-CEA 2nd
and 4th immunisation), and the control groups. However, it
remains to be seen whether primed animals would produce
high or low secondary responses when injected with HH and
VLB administered continuously via osmotic pumps.
If the theory of the 'lethal' antigen is correct, why did we
observe only a 55% reduction of immunogenicity, instead of
total abrogation and perhaps tolerance? One explanation is
that since the toxic compound (VLB) is not covalently linked
to the antibody, it is in constant association and dissociation
with it. As soon as VLB dissociates, it is rapidly removed
from the circulation, whereas bound onto the antibody, its
half life only increases slightly (Figure 1). We found that 5 h
after i.v. administration of the HH/VLB complex at a MR
1:1, almost all the antibody was present in the circulation,
but associated with only 2-5% of the initial amount of VLB
(Figures 1 and 3). B-cells that escape the first 'attack'
initially, may later capture the uncojugated mouse Ig, pro-
liferate, and eventually secrete their anti-mouse Ig antibodies.
Thus, we tried to keep the antibody's binding sites occupied
with the drug, by maintaining a constant level of VLB in the
blood, over a given period of time. This was done using
subcutaneously implanted osmotic mini-pumps that released
the drug slowly into the circulation (Figure 2).
Under these conditions, the rabbit anti-mouse Ig primary
response was further reduced, giving an overall reduction of
80% (Figure 6a). The relative absence of anti-mouse Ig
antibodies was also supported by the fact that 7 days after
administration, there was still HH in circulation, at a time
when all anti-CEA in the controls had been cleared from
circulation, probably as antigen-antibody complexes (Table
I). On days 12 and 60, the reduction of the immune response
was 55-63% (Figure 6b and c), an increase in the response,
relative to that at day 7, of 20-25%. This was not expected,
since by day 12 there was no Ig remaining in the circulation
to stimulate the B-cells (Table I), although there was pre-
sumably a reservoir of trapped antigen in/on antigen-pre-
senting cells. In addition, no anti-VLB response was
observed.
In conclusion, it appears that in our animal model the
mouse monoclonal antibody-drug complex is less immuno-
genic, due to specific inactivation of anti-mouse Ig B-cells.
Our data, therefore, support the antigen 'suicide' theory. We
believe that a carefully designed molecule can be toxic to
immunocompetent cells and hence become non-immuno-
genic. The fact that there was no change in the immune
response when the drug was covalently linked onto the anti-
body demonstrates the importance of the non-covalent link-
age for the release of active drug. In addition, we detected no
anti-VLB antibodies, although the drug does become
immunogenic when covalently linked to a carrier (Corvalan
& Smith, 1987. The fact that the immune response was not
fully suppressed may be because the drug is not effective
against non proliferating antigen presenting cells, such as
macrophages. Whereas T-cell independent responses can be
totally abrogated using a drug-conjugated 'lethal' antigen in
vivo (Abu-Hadid et al., 1987, 1988), our immunoglobulin,
like any other thymus-dependent antigen, can be effectively
processed by antigen-presenting cells, and exposed to T-cells,
which in turn may trigger low affinity mouse Ig specific
B-cells, that escaped the first 'attack'. This is also supported
by our data showing that when the 'immunosuppressive'
VLB/Ig complex is present in the circulation, the anti-Ig
response is limited to 20% of the normal. However, when the
complex is fully catabolised, the anti-Ig response increases to
40-45% of the normal.
Our drug-conjugate triggered a low immune response.
Similar conjugates have been reported to be totally immuno-
suppressive (Durrant et al., 1989). This may be attributed to
our particular antigen and animal used, and to the amount
or route by which the Ig was administered. We designed our
experiments to be as close to the clinical situation as possible.
The bispecific antibody used as antigen is an anti-tumour
monoclonal antibody, which has been used to target vinblast-
ine to established tumours (Corval'an et al., 1987b; Smith et
al., 1990). It was administered to rabbits at a concentration
equivalent to that desired in clinical therapy, and at this dose
in the absence of VLB it was very immunogenic. Never-
theless, a high degree of specific suppression was achieved
under conditions where the antibody was associated with
VLB and fully retained its anti-tumour properties. We appre-
ciate that our animal experiments could be improved further
by modifying the amount of drug-complex injected, and by
changing the route of administration or even the cytostatic
drug used.
Ultimately, what remains to be seen is whether this mono-
clonal antibody/VLB complex is also less immunogenic in
patients with cancer, something that would be of great value,
even if total abrogation of the anti-Ig immune response
cannot be achieved.
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